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Background: Sunitinib (VEGFR/PDGFR inhibitor) and everolimus (mTOR inhibitor) are both approved for advanced renal cell
carcinoma (RCC) as first-line and second-line therapy, respectively. In the clinics, sunitinib treatment is limited by the emergence of
acquired resistance, leading to a switch to second-line treatment at progression, often based on everolimus. No data have been
yet generated on programmed alternating sequential strategies combining alternative use of sunitinib and everolimus before
progression. Such strategy is expected to delay the emergence of acquired resistance and improve tumour control. The aim of our
study was to assess the changes in tumours induced by three different sequences administration of sunitinib and everolimus.
Methods: In human Caki-1 RCC xenograft model, sunitinib was alternated with everolimus every week, every 2 weeks, or
every 3 weeks. Effects on necrosis, hypoxia, angiogenesis, and EMT status were assessed by immunohisochemistry and
immunofluorescence.
Results: Sunitinib and everolimus programmed sequential regimens before progression yielded longer median time to tumour
progression than sunitinib and everolimus monotherapies. In each group of treatment, tumour growth control was associated with
inhibition of mTOR pathway and changes from a mesenchymal towards an epithelial phenotype, with a decrease in vimentin and
an increase in E-cadherin expression. The sequential combinations of these two agents in a RCC mouse clinical trial induced
antiangiogenic effects, leading to tumour necrosis.
Conclusions: In summary, our study showed that alternate sequence of sunitinib and everolimus mitigated the development of
mesenchymal phenotype compared with sunitinib as single agent.
The incidence of renal cell carcinoma (RCC) has been rising
steadily and now accounts for 2–3% of all adult cancers worldwide
(Cohen and McGovern, 2005; Ljungberg et al, 2013). Clear cell
carcinoma (ccRCC) stands as the main pathological subtype
(80–90%), papillary RCC and chromophobe RCC being the two
other major types of RCC according to the WHO tumour
classification. Recent data from The Cancer Genome Atlas (TCGA)
identified ccRCC as a highly metabolically deregulated cancer and
a model for the role of a metabolic shift or ‘Warburg effect’
observed in the acquisition of cell malignancy. Molecular
characterisation of ccRCC and preclinical investigations high-
lighted the importance of the von Hippel–Lindau (VHL) gene
alterations (Creighton et al, 2013), inhibition of VHL function
through mutations, or epigenetic silencing occurring B60–75% of
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tumours (Gossage et al, 2014). von Hippel–Lindau is an E3
ubiquitin ligase that targets the hypoxia-inducible transcription
factors (HIFs), HIF1a and HIF2a, for degradation (Cockman et al,
2000). von Hippel–Lindau loss-of-function induces HIF1a stabi-
lisation and the constitutive transcription of several genes involved
in differentiation, angiogenesis, and metabolism regulation (Pugh
and Ratcliffe, 2003; Chiatar et al, 2013; Semenza, 2013). Integrated
analyses from the TCGA also highlighted that other pathways,
especially the chromatin remodelling and PI3K/AKT/mTOR path-
ways, were important in ccRCC tumourigenesis (Creighton et al,
2013). Interestingly, alterations in the PI3K/AKT/mTOR pathway
can be identified in about 28% of tumours and are only partially
overlapping with VHL dysfunctions. Consistent with metabolic
dysfunctions in ccRCC, downregulation of the AMP-activated kinase,
upregulation of pentose phosphate and fatty acid synthesis pathway
genes, as well as upregulation of the PI3K/AKT/mTOR pathway
correlated with worse survival (Creighton et al, 2013).
As a result of HIF activation by hypoxia or VHL mutations, as
well as mTOR pathway dysfunctions, ccRCCs also acknowledged
as highly vascularised, mainly through the paracrine secretion of
vascular endothelial growth factors (VEGFs) by cancer cells.
Inhibition of the VEGF receptors (VEGFRs) by small tyrosine
kinase inhibitors (TKIs), such as sunitinib that was the first TKI
approved for advanced RCC, markedly improved the progression-
free survival (PFS) and the overall clinical outcome of these
patients (Schoffski et al, 2006; Faivre et al, 2006a). Sunitinib has a
long stand as the standard of care for first-line therapy (Motzer
et al, 2007) but despite evident clinical benefits, it is now accepted
that most patients eventually progress after few months of therapy
(Faivre et al, 2007). Loss of sunitinib activity was thought to be due
to tumour cell plasticity that allows tumour cells, endothelial cells,
and pericytes to adapt to their changing VEGFR-independent
microenvironment by activating other survival and angiogenic
pathways (Gassenmaier et al, 2013; Huang et al, 2013; Lu et al,
2013; Zhang et al, 2013). Data have also suggested that tumour
adaptation to angiogenesis inhibition may trigger tumour aggres-
siveness, facilitating occurrence of metastasis (Ebos et al, 2009;
Paez-Ribes et al, 2009). In renal cancer models, data have suggested
that the PI3K/AKT/mTOR pathway could be involved in resistance
to sunitinib (Makhov et al, 2012). Currently, clinical evidences of
resistance to sunitinib lead most patients to switch for a second-
line therapy based on either mTOR inhibitors (Faivre et al, 2006b)
such as everolimus (Motzer et al, 2008, 2010) or on small TKIs
whose inhibitory spectrum differs to some extend from sunitinib,
such as sorafenib or pazopanib (Keisner and Shah, 2011; Afonso
et al, 2013). In fact, emerging evidence showed that everolimus
may display both antiangiogenic and antitumour activities and that
these effects may counteract sunitinib resistance (Lane et al, 2009;
Fuereder et al, 2010). Taking advantage of potentially distinct
mechanism of action on cell signalling, authors have attempted to
combine everolimus with sunitinib (Fuereder et al, 2010).
However, these attempts were limited by significant, that is, severe
dose-limiting acute and chronic toxicities (Molina et al, 2012).
Concomitant use of sunitinib and everolimus being prohibited
by toxicity, sequential administration of both drugs has been
proposed with the goal of switching drugs at fixed time points
before acquired resistance may have a chance to emerge. In this
study, we designed a preset strategy using sequential administra-
tion of sunitinib and everolimus before progression in human RCC
xenograft models.
MATERIALS AND METHODS
Drugs. Everolimus was supplied by Novartis (Novartis Pharma
SAS, Reuil-Malmaison, France). Sunitinib was purchased from LC
Laboratories (Woburn, MA, USA). Sunitinib powder was dissolved
immediately before gavage in a sterilised solution containing 0.5%
carboxymethylcellulose, 0.4% Tween 80, 1.8% NaCl and 0.9%
benzyl alcohol. Everolimus as a microemulsion was suspended in
sterile water at an appropriate concentration and was admini-
strated within 2 h.
Cell line. Caki-1 ccRCC cell line was obtained from the ATCC
(Rockville, MD, USA). The Cells were grown as monolayers in
RPMI medium supplemented with 10% foetal calf serum, 2mM
glutamine, 100 units per ml penicillin and 100 mgml 1 strepto-
mycin (Invitrogen, Cergy-Pontoise, France), at 37 1C in a
humidified 5% CO2 atmosphere, and regularly checked for absence
of mycoplasma.
Tumour cells xenografts in nude mice. All the in vivo experi-
ments were carried out with ethical committee approval and met
the standards required by the UKCCCR guidelines. A total of
5 106 Caki-1 renal cancer cells were injected subcutaneously into
the flank of female athymic nude mice (Janvier, Le Genest St Isle,
France). One week after cell inoculation, all mice developed single
subcutaneous palpable tumours of B50–100mm3. Mice were
arbitrarily placed in the groups of treatment. Mice were then
treated 5 days a week by oral gavages with 60mg kg 1 per day
sunitinib (n¼ 5), 10mg kg 1 per day everolimus (n¼ 5), or
sequential regimens that alternate sunitinib and everolimus for 1
(n¼ 5), 2 (n¼ 5), or 3 weeks (n¼ 5), or only with the sterilised
solution (control group, n¼ 6). To choose the everolimus
concentration, a pilot study was performed in this model using
five different concentrations as following: 1, 2.5, 5, 10, and
20mg kg 1 per day. Tumour growth inhibition was observed from
5mg kg 1 per day, and was significant at 10 and 20mg kg 1 per
day. To minimise the toxicity in the sequential regimens, we
choose the lowest effective concentration of everolimus, that is,
10mg kg 1 per day. Moreover, this concentration was shown to
delay tumour growth in vivo (O’Reilly et al, 2006; Larkin et al,
2012).Tumour volumes were measured twice a week along two
major axes using a caliper. Tumour volumes were calculated as
follows: tumour volume¼ ((length) (width2))/2. Tumours were
considered progressive when, among the three consecutive
increasing measures, tumour volumes displayed a 30% increase
compared with the smallest tumour measurement (NADIR). Time
to tumour progression (TTP) was defined as the time from start of
drug administration to first evidence of tumour progression.
Our study defined two main tumour responses as following:
(i) sustained (ST) tumour control, that is, partial response followed
by tumour volume stabilisation or slow tumour volume progres-
sion, or (ii) tumour progression (PG), that is, tumour volume
stabilisation followed by quick disease progression. Partial response
in the treated groups was defined as a minimum of 30% tumour
volume reduction from baseline. At day 66, when all placebo-
treated mice were killed, ST tumour control was confirmed
whether tumour volumes had not doubled in size from baseline. If
tumour volumes were over twice the baseline volumes, mice were
considered to belong to the tumour PG group. When tumour
volumes reached 2 cm3, mice were killed. Body and tumour weight
were recorded. After mice were killed, tumours were excised and
OCT embedded (VWR, Fontenay-sous-bois, France) to prevent
tissue degradation from frozen conservation.
Immunohistochemistry analysis. The immunohistochemical pro-
cedure was performed on OCT-embedded subcutaneous tumour
stained with haematoxylin and eosin (HE), and carbonic anhydrase
9 (CA-IX) (NB-100-417, Novus Biologicals, Littleton, CO, USA)
using an automated immunohistochemical stainer. The images
were captured and analysed with a Zeiss Observer Z1 microscope
(Zeiss, Oberkochen, Germany). Quantifications were performed
using Image J software (NIH, Bethesda, MD, USA) for HE and
CA-IX staining. Necrotic areas were defined as tumour section
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areas where cells displayed pycnotic nucleus or no nucleus.
Necrotic tissues are characterised by a strong pink colour, as
observed in Figure 3.
Immunofluorescence analysis. Tumour slices were fixed in 4%
paraformaldehyde (Invitrogen, Cergy-Pontoise, France), washed
with PBS, where after unspecific sites were blocked using PBS
containing 10mgml 1 BSA for 1 h at room temperature (RT).
Slices were then incubated with rat anti-human CD31 antibodies
(550174BD Biosciences, San Jose, CA, USA), rabbit anti-human
phospho-S6 ribosomal protein (pS6) (1/100), vimentin (1/100), or
E-cadherin (1/100) primary antibodies (Cell Signaling, St Quentin
en Yvelines, France) at RT for 1 h, followed by incubation with the
secondary antibodies Alexa Fluor (1/200) (Molecular Probes, Life
Technologies, Saint-Aubin, France) for 1 h at RT and in the dark.
Nuclei were stained with 5mgml 1 DAPI. Image analysis was
performed using Zeiss Observer Z1 fluorescent microscope (Zeiss,
Oberkochen, Germany) and Image J software.
Statistical analysis. The significance of variability between the
results of each group and its corresponding control was determined
by unpaired t-test using GraphPad Prism 5 (GraphPad Software
Inc., San Diego, CA, USA). For immunohistochemistry and
immunofluorescence analysis, values represent the means±s.e.m.
of at least five quantifications per animal. Survival curves were
plotted according to Kaplan–Meier.
RESULTS
Effects of sequential administrations of sunitinib and
everolimus on tumour PG. Caki-1 cells were subcutaneously
injected into nude mice. After 1 week, when tumours became
palpable (50–100mm3), the mice were randomly assigned to six
treatment groups including vehicle control, sunitinib 60mg kg 1
per day, everolimus 10mg kg 1 per day, or alternate administra-
tion of sunitinib (S) and everolimus (E) every week (1W), every 2
weeks (2W), or every 3 weeks (3W) (Figure 1A). Tumour growth
was followed by measuring tumour volume twice a week
(Supplementary Figure 1). Tumours were considered progressive
when, among three consecutive increasing measures, tumour
volumes displayed a X30% increase compared with the smallest
tumour measurement. Median TTP (mTTP) in vehicle, sunitinib,
and everolimus groups was 24, 36, and 50 days, respectively
(Figure 1B). When analysed as a single group, alternated sequential
treatments improved the mTTP to 59 days. More specifically,
mTTP in the 1, 2, and 3W groups were 64, 59, and 59 days,
respectively (Figure 1C). This improvement represented a 2.5-fold
increase in mTTP compared with the control treatment group and
a 20–80% increase compared with single agents sunitinib or
everolimus.
Effects of preset sequences of sunitinib and everolimus on
tumour angiogenesis. Tumour angiogenesis was analysed by
CD31 staining, a surface marker of endothelial cells allowing
evaluation of the number of vessel and the vascular area of
tumours (Figure 2A). In all treated groups, the number of vessels
was significantly decreased relative to the control group
(Figure 2B). In accordance with the known antiangiogenic effects
of sunitinib, sunitinib alone and alternated sequences containing
sunitinib induced a reduction in the number of vessels in
comparison to treatment with everolimus alone. In addition, the
vascular areas were significantly decreased in all of the treated
tumours compared with control, confirming that sunitinib- and
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Figure 1. TTP of RCC xenografts treated with vehicle, sunitinib, everolimus, and sequences. Mice groups according to the treatment protocols
(A) Kaplan–Meier evaluations for mice treated with 60mgkg 1 per day sunitinib, 10mgkg 1 per day everolimus, sequential combination of
60mgkg1per day sunitinib, and 10mgkg 1 per day everolimus as a single group (B) composed with treatment of alternate drugs administration
every week (1W), every 2 weeks (2W), and every 3 weeks (3W) (C).
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everolimus-based treatments could directly affect angiogenesis
(Figure 2C). Among the alternated sequential regimens, the 1W
regimen displayed the strongest effects on vascular area reduction,
whereas the 2 and 3W regimens had similar effects as the single
agents sunitinib or everolimus.
Discrete effects of sunitinib and everolimus on necrosis and
hypoxia induction. Necrosis, as determined by HE staining, was
significantly increased in the tumours treated with sunitinib alone
or in sunitinib/everolimus sequential combination as compared
with vehicle or everolimus alone (Figure 3A). Necrotic areas in
tumours treated with sunitinib monotherapy were increased by
two-fold reaching 47.3% of the tumour area compared with 23.6%
in the control-treated tumours (Figure 3B). Similar increase was
observed in tumours treated with the alternated sequences of
sunitinib and everolimus with necrosis reaching 43.7% of the
tumour area. Taken individually, necrotic areas in the 1W, 2W,
and 3W regimens reached 38.1%, 52.3%, and 40.6% of the tumour
area, respectively. Treatment with everolimus alone did not induce
significant changes in necrotic areas relative to control (27% vs
23.6%), suggesting that in all regimens, necrosis was a consequence
of sunitinib administration.
Staining with anti-CA-IX antibodies was performed to assess
occurrence of hypoxia within treated tumours (Figure 3C,
Supplementary Figure 4). The CA-IX expression is often regarded
as a surrogate marker for HIF expression; the latter being a very
unstable biomarker that could be technically difficult to evaluate
using immunohistochemistry. Basal CA-IX staining covered 57.7%
of the surface of control tumours (Figure 3D). Sunitinib both as a
single agent and in sequential regimens increased the hypoxic area
to 69.5% and 76.1% of the tumour area, respectively. In the 1W,
2W, and 3W regimens, hypoxic areas increased to 68.4%, 84.1%,
and 75.9% of the tumour area, respectively. In contrast, everolimus
alone did not induce significant increase hypoxic areas compared
with control (62.7% vs 57.7%). As for necrosis, increase in hypoxic
areas seemed dependent on sunitinib administration rather than
everolimus.
Angiogenesis and mTOR pathway variations according to
tumour response. We observed two main tumour behaviours
that may characterise the sensitivity to the different treatments:
(i) ST tumour control, that is, partial response followed by tumour
volume stabilisation, and (ii) tumour PG, that is, tumour volume
stabilisation followed by quick disease progression (see Materials
and methods). The distribution of mice into the two groups of
response was as followed. Forty percent of the tumours were
characterised by ST tumour control in the sunitinib (n¼ 2/5),
everolimus (n¼ 2/5), and sunitinib/everolimus treatment groups
(n¼ 6/15) (see Supplementary Table 1). Slight differences were
observed within the alternated regimens, with 40%, 20%, and
60% of ST tumours in the 1W (n¼ 2/5), 2W (n¼ 1/5), and 3W
(n¼ 3/5) regimens, respectively (see Supplementary Table 1).
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Figure 2. Immunofluorescence analysis of angiogenesis from Caki-1 tumour sections stained with CD31. Representative pictures of CD31
staining for each group of treatment. Bar graph¼ 200mM (A). Angiogenesis was quantified using Axiovision software (Zeiss, Oberkochen,
Germany); values represent the means±s.e.m. of at least five quantifications per animal. Number of vessels (B) and vascular lumen area (C) per
field were measured for mice with tumours treated with vehicle control (C), 60mgkg1 per day sunitinib (S), 10mgkg 1 per day everolimus (E),
sequential combination of 60mgkg1 per day sunitinib, and 10mgkg1 per day everolimus as a single group (S/E) composed with treatment of
alternate drugs administration every week (1W), every 2 weeks (2W), and every 3 weeks (3W). * Symbol stands for statistical analysis of treatment
groups relative to control and y symbol stands for analysis relative to everolimus. *** or yyyPo0.005, ** or yyPo0.01, * or yPo0.05.
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As expression of HIF in our model is not constitutively driven by
VHL mutation, changes in tumour angiogenesis and mTOR
pathways are considered as potentially adaptive mechanisms in
response to the stress induced by sunitinib and everolimus. Vessel
numbers and vascular lumen areas were reduced by 2.5–4-fold in
all the treatment groups compared with control, reflecting a strong
antiangiogenic effect. This effect was independent of the progres-
sion status of the tumours with the exception of tumours
controlled by sunitinib alone, which were characterised by reduced
vascular lumen area and increased necrosis (Supplementary
Figure 2).
We then assessed the expression of the pS6, a downstream target
of mTOR (Figure 4A) in all groups of tumours. In controlled
tumours, pS6 expression was significantly decreased compared
with the pS6 expression in progressive tumours, except for
tumours that were treated with sunitinib as a single agent.
Everolimus alone, 1W, 2W, and 3W regimens reduced pS6
expression by 60%, 38%, 70%, and 27%, respectively, in controlled
tumours as compared with progressive tumours (Figure 4B). Of
note, pS6 expression in progressive tumours was decreased in 2
and 3W groups compared with the other regimens (control, 1W,
sunitinib, and everolimus monotherapy) indicating a more efficient
downregulation of the mTOR pathway with those two sequential
combinations. In conclusion, tumours controlled by the treatment
were characterised by reduced angiogenesis and mTOR pathway
inhibition, whereas progressive—that is, resistant—tumours were
characterised by sustained mTOR pathway activity.
Lack of response to targeted therapy and mesenchymal
differentiation. Drug-induced hypoxia in tumours may trigger
survival pathways among which epithelial–mesenchymal transition
(EMT) seems to have a major role. Furthermore, as both
angiogenesis and mTOR pathway inhibition may affect cellular
differentiation, we evaluated vimentin and E-cadherin expression
in tumours (Figure 5A). In the vehicle-treated group, tumours
expressed both vimentin (53.9% of the tumour area) and
E-cadherin (35.7%) displaying a mixed phenotype with a
vimentin/E-cadherin ratio of 1.5 (Figure 5D). In all treatment
groups, controlled tumours displayed a decrease in vimentin
expression by 73% and 79% when treated by sunitinib and
everolimus as single agents, respectively, and by 33% when
considering all alternated sequences as a single group. In details,
tumour sustainably controlled by 1W, 2W, and 3W regimens were
characterised by a reduction in vimentin expression of 42%, 46%,
and 31%, respectively (Figure 5B). In contrast, E-cadherin
expression increased by 93% in the sunitinib monotherapy group
and by 33% in the alternated sequence groups with some
differences among regimens. For instance, controlled tumours in
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Figure 3. Immunohistochemistry analysis of Caki-1 tumour sections stained with HE and for CA-IX. Representative pictures of HE staining (A) and
CA-IX (C) for each group of treatment. Bar graph is 200mM for HE staining and 100mM for CA-IX staining. Necrosis (B) and hypoxia (D) were
quantified by Image J software for mice with tumours treated with vehicle control (C), 60mgkg1 per day sunitinib (S), 10mg kg 1 per day
everolimus (E), sequential combination of 60mgkg 1 per day sunitinib, and 10mgkg 1 per day everolimus as a single group (S/E) composed
with treatment of alternate drugs administration every week (1W), every 2 weeks (2W), and every 3 weeks (3W). Values represent the
means±s.e.m. of at least five quantifications per animal with five animals per group, * Symbol stands for P-values relative to control and y symbol
stands for analysis relative to everolimus, ** or yyPo0.01, * or yPo0.05.
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the 2W and 3W groups displayed 70% and 54% increase in
E-cadherin expression, respectively, whereas tumours treated in the
1W regimen displayed a 38% reduction in E-cadherin expression
(Figure 5C). Similar to the 1W regimen, controlled tumours in the
everolimus monotherapy group displayed a 10% decrease in
E-cadherin expression. Despite these differences among the
treatment groups, the ratio of vimentin/E-cadherin expression
decreased in all groups compared with the vehicle-treated tumours,
suggesting epithelial differentiation when tumours are controlled
by the treatments (Figure 5D). Conversely, in most progressive
tumours the proportion of vimentin-positive surface did not
change, except a slight decrease in the sunitinib monotherapy
group (Figure 5B). Three treatment groups displayed reduced
E-cadherin expression among progressive tumours compared with
control-treated tumours (sunitinib monotherapy, 2 and 3W
regimens), whereas two treatment groups displayed a modest
increase (everolimus monotherapy and 1W regimen) (Figure 5C).
As a consequence, in these progressive tumours the vimentin/
E-cadherin ratio increased in three groups (sunitinib monotherapy,
2 and 3W regimens) and slightly decreased in two other groups
(everolimus monotherapy and 1W regimen) (Figure 5D). These
results suggested that progressive tumours under treatment tend to
exacerbate a mesenchymal differentiation, especially in the
sunitinib monotherapy subgroup, whereas tumours sustainably
controlled retain more epithelial phenotypes.
DISCUSSION
Sunitinib and everolimus are both approved for the treatment of
advanced RCC in first-line and second-line therapy, respectively.
In most patients, the switch from first-line treatment with TKI to
second-line everolimus is made upon occurrence of documented
development of tumour PG. Sunitinib is regarded as an
antiangiogenic agent inducing vascular disruption, hypoxia, and
tumour necrosis. Either as a consequence of pharmacological
mechanisms or as a result of constitutively activated hypoxia
pathways in the tumour, some clinical data and data from animal
models have also suggested that the development of resistance was
associated with a more aggressive phenotype. Consequently,
attempts have been made to counteract acquired resistance to
sunitinib and clinical trials have been developed aiming to switch
between active compounds displaying distinct mechanisms of
action before the occurrence of acquired resistance.
The aim of our study was to look at changes in human tumours
exposed to sequential administration of sunitinib and everolimus
to provide information that could serve for clinical trials aiming at
delaying tumour PG in RCC patients. In our study, we tested three
different sequences of sunitinib and everolimus consisting of every
week (1W), every 2 weeks (2W), and every 3 weeks (3W)
alternation (Figure 1A). Although the small number of animals
limits statistics in terms of TTP in this study, all evaluated
sequences yielded longer mTTP than sunitinib and everolimus
given as a continuous daily dosing as single agents. This
observation supports the hypothesis that treatment alternations
before progression could postpone the emergence of tumour PG.
In our study, single agent sunitinib yielded shorter mTTP
compared with everolimus monotherapy (36 days vs 50 days).
Similar observations were made in vivo in other models showing
increased median survival of mice treated by everolimus first line
compared with sunitinib (Rosa et al, 2013). However, this trend
was not observed in clinical trials in which median PFS for first-
line sunitinib was consistently superior to everolimus (Motzer et al,
2007, 2013).
Recent data from literature highlighted the possible correlation
between EMT and sunitinib resistance in ccRCC (Hammers et al,
2010). Interestingly in a mammary epithelial cells model, the
inhibition of mTOR pathway was found to activate EMT
(Mikaelian et al, 2013). In our study, tumours treated with
everolimus in monotherapy or in alternated sequential regimens
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Effects of sunitinib and everolimus on tumour differentiation BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.578 91
Control
80
Ex
pr
es
sio
n 
of
 v
im
en
tin
pe
r f
ie
ld
 (%
)
Ex
pr
es
sio
n 
of
 E
-c
ad
he
rin
pe
r f
ie
ld
 (%
)
*
***
***
*
*
*
*** *
*
#
#
60
40
20
0
PG
C S E S/E 1W 2W 3W
C S E S/E 1W 2W 3W
C S E S/E 1W 2W 3W
PG ST PG ST PG ST PG ST PG ST PG ST
PG PG ST PG ST PG ST PG ST PG ST PG ST
PG PG ST PG ST PG ST PG ST PG ST PG ST
80
NS
60
40
20
0
8
7
6
3
2
1
0
Vi
m
en
tin
E-
ca
dh
er
in
Progressive
tumour
Progressive
tumour
Sustained
tumour
control
Sustained
tumour
control
Sunitinib Everolimus 1W 2W 3W
%
 V
im
en
tin
 e
xp
re
ss
io
n/
%
 E
-c
ad
he
rin
 e
xp
re
ss
io
n
A
B
C
D
Figure 5. Immunofluorescence analysis of Caki-1 tumour sections stained with EMT markers. Representative pictures of vimentin and
E-cadherin staining for each group of treatment (A).Vimentin (B) and E-cadherin (C) expression were quantified by Image J software for mice
with tumours treated with vehicle control (C), 60mg kg 1 per day sunitinib (S), 10mg kg1 per day everolimus (E), sequential combination of
60mg kg 1 per day sunitinib, and 10mg kg 1 per day everolimus as a single group (S/E) composed with treatment of alternate drugs
administration every week (1W), every 2 weeks (2W), and every 3 weeks (3W). Ratios of vimentin expression to E-cadherin expression were
calculated in each treatment group (D). For each treatment group a double bar graph represent in one hand the mice with quick progressive
disease (PG) and in the other hand the mice with sustained (ST) tumour control. Values represent the means±s.e.m. of at least five
quantifications per animal with five animals per group, ***Po0.005, **Po0.01, *Po0.05, NS¼non significant, #symbol stands for no calculable
P-values due to the small sample number.
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displayed a higher level of vimentin expression than tumours
treated with sunitinib alone consistent with the observation that
everolimus may induce mesenchymal differentiation. Interestingly,
the ratio of vimentin over E-cadherin expression was different in
the alternative sequences compared with monotherapies. This
suggests that the tumour cell biology responded differently to
alternations of drugs than to continuous exposure to the same
inhibitor.
Sequential regimens were all efficient in inhibiting angiogenesis
as determined by reduction in the number of tumour vessels and
tumour vascular areas. Interestingly, as shown earlier (Lane et al,
2009), angiogenesis inhibition by sunitinib and everolimus
proceeded from different mechanisms as neither hypoxia nor
necrosis was involved in tumours treated by everolimus alone. In
addition, only mice treated with sunitinib monotherapy presented
controlled tumours characterised by lower vessel size compared
with progressive tumours. In fact, it has been suggested that
everolimus was more efficient on mature vessels than sunitinib that
mainly affected unstable neoangiogenesis (Lane et al, 2009).
Alternate combinations of sunitinib and everolimus may thus
target both immature and mature vessels, increasing antiangio-
genic activity. New studies are questioning the use of early switch
to everolimus after first-line TKI failure instead of a prolonged TKI
exposure in second line (Calvani et al, 2013). However, looking at
TTP and pS6 inhibition, our data suggested that everolimus
remained efficient in a sequential combination strategy in which
early switches are done before progression. The degree of pS6
inhibition was even increased in the sequential combination
strategy compared with everolimus monotherapy. This may be
explained by the fact that programmed switches between ever-
olimus and sunitinib could delay the occurrence of mechanisms
associated with drug resistance, such as the induction of AKT
activation by a negative feedback loop upon mTOR inhibition that
has been previously reported (O’Reilly et al, 2006).
How alternate sequences of sunitinib and everolimus translate
into clinical setting remains difficult to evaluate in the absence of
specific clinical trial. In the RECORD-3 study comparing sunitinib
until progression followed by everolimus vs the reverse sequence,
the investigators showed that sunitinib first line followed by
everolimus was superior to everolimus first line followed by
sunitinib in terms of first-line PFS and overall survival. However,
as450% of patients were unable to cross over, it remains difficult
to compare second-line with first-line median PFS. However, in the
RECORD-1 trial comparing everolimus to placebo after sunitinib
or sorafenib failure, median PFS was 4.9 months, which represent
B50% of first-line median PFS of 10.7 months, assuming a cross
trial comparison (Motzer et al, 2007, 2008). In our mice trial, the
median TTP was 59 days for the alternated sequences of treatment,
which represent a 64% increased compared with the mTTP of
sunitinib. Rosa et al (2013) recently published a study observing
the impact of everolimus after 5 weeks of sunitinib treatment and
demonstrated that the addition of everolimus slowed down tumour
growth compared with sunitinib monotherapy . In their study, they
also report a 60% increase in overall survival for the sequential
treatment over monotherapy (97 vs 61 days). All together, these
data suggest that a programmed sequential strategy giving
sunitinib and everolimus without waiting for progression may be
considered as a potential option for designing clinical trials in
patients with advanced RCC. In fact, using TKI or everolimus often
induce transient toxicities that could be clinically limiting or
unbearable for patients leading to therapeutic interruption
(Molina et al, 2012). In this study, no significant weight loss or
changes in animal behaviour was observed in mice treated with
alternate sequences, indicating no toxicity of these treatments
(Supplementary Figure 3).
In summary, the use of a sequential combination strategy using
alternate treatments with sunitinib and everolimus may be an
interesting approach to control tumour PG and postpone the
emergence of resistance mechanisms such as the EMT. At least
three clinical trials are underway evaluating alternate sequence of
sunitinib and everolimus or temsirolimus in patients with
advanced RCC (ANZUP 0901, NCT01784978 and NCT01517243).
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